This is a preview of subscription content, log in via an institution to check access.
Notes
2017/2018 euros
progression-free survival
Reference
Terpos E, et al. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy Journal of Medical Economics : 10 Apr 2019. Available from: URL: https://doi.org/10.1080/13696998.2019.1606002
Rights and permissions
About this article
Cite this article
Denosumab cost effective in patients with multiple myeloma. PharmacoEcon Outcomes News 826, 9 (2019). https://doi.org/10.1007/s40274-019-5811-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5811-z